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Abstract
Colorectal cancer is among the most frequent malignant tumours. Liver metastases
develop in 70–75% of patients affected by colorectal carcinoma. Nowadays, surgical
treatment can significantly improve the 5-year survival ranging 40–58% of the patients
undergoing liver surgery. The operation extent ranges from nonanatomic minor
resection to major hepatectomy. Recently, liver transplantation has been performed
for metastatic colorectal cancer. Laparoscopic approach and robotic surgery can be
used by experienced specialists. The prerequisites for successful surgical treatment
include exact radiologic diagnostics to determine the number and size of metastases
and their association with anatomic structures; individual anatomic peculiarities and
remnant liver volume, ranging 20–40% in respect to functional liver status. Magnetic
resonance imaging is the most sensitive method that has marked advantages in the
diagnostics of lesions smaller than 1 cm and metastases on the background of liver
steatosis. Computed tomography is an acceptable alternative that benefits from high
spatial resolution and optimal reconstructions to evaluate the anatomy. Additional
information can be obtained from tumour markers, including traditional, e.g.,
carcinoembryonic antigen (CEA) and novel, e.g., microRNAs. To ensure that each
colorectal cancer patient receives the best care, the medical society should be well
informed about the possibilities in the treatment of liver metastases of colorectal
cancer regarding the methods, indications and limits.
Keywords: Colorectal cancer, liver metastasis, liver resection, magnetic resonance
imaging
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1. Introduction
Colorectal cancer (CRC) represents one of the leading malignant tumours both by incidence
and death rate [1, 2]. Metastatic spread to liver occurs in 70–75% of patients, and 20–35% of
CRC patients present with synchronous liver metastases [1, 3, 4]. Although the presence of
metastatic disease significantly adversely affects the survival, a wide scope of treatment
options exists. To ensure that each colorectal cancer patient receives the best care, the medical
society should be well informed about the possibilities in the treatment of liver metastases of
colorectal cancer regarding the methods, indications and limits.
Surgery is the preferred option for long term survival. The operation extent ranges from major
hepatic resection (trisegmentectomy, hepatectomy, extended hepatectomy, and hemihepatec‐
tomy) to parenchyma-sparing minor resection such as segmentectomy or wedge resection [4].
Laparoscopic approach and robotic surgery can be considered, especially in advanced centres
[5, 6]. In patients with questionable adequacy of the liver remnant and wide intrahepatic
tumour spread, portal vein occlusion, forced liver hypertrophy and staged resection can be
helpful [7, 8]. Recently, liver transplantation for metastatic colorectal cancer has been per‐
formed [9].
Surgery at present assumes significant role in treatment of metastatic liver lesions. However,
it demands not only appropriate surgical technique but also correct preoperative diagnosis
and reliable plan for postoperative treatment.
Adequately timed and exact imaging is necessary prior to the surgical or nonsurgical treatment
to reveal the metastases and assess the feasibility of resection. Magnetic resonance imaging
(MRI), computed tomography (CT), ultrasonography (US) and 18F-2fluoro-D-glucose posi‐
tron emission tomography in association with computed tomography (PET-CT) are used for
imaging metastatic lesions in the liver [1]. The radiologic evaluation can be combined with
traditional and novel cancer markers [10–12] and biopsy examination. Among serological
markers, carcinoembryonic antigen (CEA) has been used traditionally despite the limitations
[4] and lack of unified guidelines. MicroRNAs represent a rapidly advancing research field
hopefully yielding diagnostic blood tests to diagnose the cancer by location and to identify the
presence of residual tumour or early recurrence.
If the surgical treatment is not possible, other options must be considered, including systemic
or transarterial chemotherapy; embolisation; ablation by cryotreatment, radiofrequency or
microwaves; or radiotherapy and targeted external beam radio therapy [1].
Due to the wide scope of treatment options, the median survival of patients affected by
metastatic colorectal cancer has increased significantly [13, 14]. The 5-year and 10-year survival
reaches 58% and 36%, correspondingly [15].
In conclusion, liver metastases of colorectal cancer represent a frequent and serious condition.
The remarkable medical advances request dynamic systematisation of up-to-dated evidence.
The present chapter on the surgical treatment of colorectal cancer metastases is intended to
summarise the present knowledge in regard to the approach to patient with liver metastases
of colorectal cancer, discussing the diagnostics, treatment and evaluation of response.
Recent Advances in Liver Diseases and Surgery170
2. Epidemiology of colorectal cancer
Colorectal cancer is among the leading malignant tumours both by incidence and by death
rate [1]. Globally, in the year 2012, it was the 3rd most frequent cancer in men and the 2nd in
women [2]. The incidence and mortality is higher in males (Table 1). The highest incidence
rates are found in Australia and New Zealand, Europe and North America contrasting with
low incidence in Africa and South Central Asia. As shown in Table 2, the incidence is generally
higher in more developed countries [2]. The decrease in colorectal cancer incidence in USA
reflects successful screening and removal of colorectal adenomas. The incidence growth,
recently observed in Western Asia (Kuwait and Israel) and Eastern Europe (Czech Republic
and Slovakia), reflects increased prevalence of risk factors as diet, obesity and smoking.
Gender Incidence Mortality
ASR Proportion1, % ASR Proportion1, %
Males 20.6 10.1 10.0 8.0
Females 14.3 9.2 6.9 9.0
1 Among all cancers.
ASR, age-standardised ratio per 100,000.
Table 1. Global incidence and mortality attributable to colorectal cancer (2012) by Globocan data [16]
Gender and welfare
status
Incidence Mortality
ASR Cumulative risk, % ASR Cumulative risk, %
More developed areas1
Males 36.3 4.3 14.7 1.6
Females 23.6 2.7 9.3 1.0
Less developed areas2
Males 13.7 1.6 7.8 0.8
Females 9.8 1.1 5.6 0.6
1Includes Europe, North America, Australia, New Zealand and Japan.
2Includes Africa, Asia (except Japan), Latin America, Melanesia, Micronesia and Polynesia.
ASR, age-standardised ratio per 100,000.
Table 2. Incidence and mortality caused by colorectal cancer by regional welfare [2]
Colorectal cancer could be prevented avoiding obesity, alcohol, smoking and excessive
consumption of red and processed meat, as well as maintaining physical activity. There are
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also several screening methods, including guaiac-based or immunochemical test for occult
blood in stools, faecal DNA test, virtual colonoscopy by computed tomography imaging,
double-contrast barium enema, flexible sigmoidoscopy and colonoscopy [2]. MicroRNA stool
test could appear in the nearest future. Despite the possibilities of prevention and screening,
metastatic disease is common. Metastatic spread to liver occurs in 70–75% of patients, and 20–
35% of CRC patients are diagnosed with synchronous liver metastases [1, 3, 4]. Although the
presence of metastatic disease significantly adversely affects the survival, a wide scope of
treatment options exist.
3. Radiologic imaging techniques in the diagnostics of liver metastases of
colorectal cancer
The radiologic techniques of liver examination comprise computed tomography, magnetic
resonance imaging, ultrasound evaluation and fluorodeoxyglucose positron emission tomog‐
raphy [17]. CT and MRI represent the cornerstone in the diagnostics of liver metastases of
colorectal cancer [1, 18]. US has the benefits of wide accessibility and lack of irradiation.
However, it is considered a historical method in developed countries as USA [18] due to lower
sensitivity and specificity. These parameters can be improved by contrast-enhanced US [19].
Positron emission tomography (PET) has certain indications.
MRI is characterised by the highest specificity and sensitivity, especially regarding metastases
smaller than 1 cm in diameter [1, 20]. The imaging technology is based on different physical
status of water and fat protons [18]. To identify liver metastases, MRI routinely includes T1,
T2 and diffusion-weighted sequences before and after administration of gadolinium-contain‐
ing contrast agent. The CRC metastases are hypointense on T1 but hyperintense on T2 and
diffusion-weighted imaging sequences. The contrasting reveals metastasis as a hypovascular
focus with an irregular rim of enhancement [18].
In the identification of liver metastases, MRI is characterised by the highest sensitivity that
reaches 76.0–85.7% if enhancement by extracellular contrast agents and dynamic acquisition
is used. The sensitivity can be further improved by diffusion-weighted imaging. Diffusion-
weighted imaging is based on the assessment of Brownian motion of water molecules and
water diffusion within a voxel (a tridimensional pixel). As cell membranes limit the diffusion,
greater cellularity results in diffusion restriction [21]. Thus, the metastasis creates an obstacle
in water molecule diffusion and is revealed by diffusion-weighted imaging at higher sensi‐
tivity and specificity than routine MRI [17, 22, 23]. The hepatobiliary phase MRI represents
another improvement in the diagnostics of liver metastases by contrast agents that are
absorbed by hepatocytes and excreted in biliary system, e.g., gadoxetate disodium and
gadobenate dimeglumine. These agents differ from the traditional MRI contrast agents by the
dual elimination, including both biliary excretion (50%) and renal glomerular filtration, while
the traditional agents, as gadopentetic acid, are almost completely excreted via kidneys [1,
18]. The hepatobiliary phase of MRI corresponds to the peak parenchymal enhancement due
to contrast uptake in hepatocytes. It is observed 20 min after injection. Metastatic foci lack liver
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cells and therefore do not absorb hepatobiliary contrast agents. In the diagnostics of colorectal
cancer liver metastases, the sensitivity of hepatobiliary phase MRI reaches even 90–97% [1, 24,
25]. In comparison with diffusion-weighted imaging, hepatobiliary phase MRI enhances
sensitivity for the detection of colorectal cancer metastasis, e.g., from 78.3–97.5% to 94.4–
100.0%. The combination of diffusion-weighted imaging with hepatobiliary phase MRI yields
better results than isolated techniques [26].
Gadolinium-containing contrast agents can induce nephrogenic systemic fibrosis in a subfrac‐
tion of patients (2.9–4%) with severe renal insufficiency [1, 27, 28]. Sufficient enhancement
quality can be reached by half-dose gadoxetic acid [29]. However, other research groups have
not observed any case of gadoxetate-related nephrogenic systemic fibrosis in a prospective
multicentre study [30]. The risk of nephrogenic systemic fibrosis also varies by different
contrast agents [1].
In comparison with CT, MRI has advantage in the diagnostics of lesions measuring less than
1 cm and shows better ability to discriminate metastases on the background of spontaneous
or treatment-induced (e.g., 5-fluoruracil and irinotecane) liver steatosis [1, 17, 31]. However,
CT provides better resolution of anatomic details that are necessary to plan the surgery [18].
Consequently, controversies have been expressed if the liver imaging in colorectal cancer
patient should be started with CT or MRI [1, 18].
MRI is contraindicated in patients having incompatible implants, e.g., pacemakers; affected
by claustrophobia or impaired glomerular filtration rate, or unable to hold the breath for longer
than 20 seconds. CT should be performed in these patients [1, 18].
Multidetector CT can be used for chest, abdominal and pelvic imaging to reveal the total
visceral metastatic burden. Contrasting with intravenous iodinated agents is necessary to
reveal liver metastases that represent hypodense hypovascular foci with variable heterogene‐
ity, seen in portal venous phase [18]. Rim enhancement can be observed [17]. Due to low
tumour vascularity, arterial phase is more important for detection of arterial anatomy than for
identification of metastases. In nonenhanced CT, the metastases are hypointense but can be
inconspicuous [17, 18]. The possibilities of CT are limited in detection of small lesions and
inhassessment of steatotic liver. MRI is helpful in these situations. The benefits of multidetector
CT include high spatial and temporal resolution exceeding that of MRI. Thus, CT is useful for
planning before surgery. The individual anatomic features can also be detailed by CT [18].
PET-CT reflects the metabolic activity in tumour cells by analysing glucose uptake. It has
advantage in detecting extrahepatic metastatic spread [1] or local recurrence and in evaluation
of indeterminate liver lesions [17]. In a prospective study of 133 consecutive patients, PET-CT
had a major impact on staging of extrahepatic spread in 20% of patients. It resulted in upstaging
(from surgically treatable to inoperable) in 6% of patients and downstaging (from indetermi‐
nate or suspected inoperable to operable) in another 6% of patients [32]. As extrahepatic spread
is more likely in patients who already have liver metastases, PET-CT should be considered a
standard evaluation prior to curative liver surgery for metastatic colorectal cancer. PET-CT
reduces futile laparotomies by 38% [33]. Combination with diagnostic intravenous contrast-
enhanced CT is strongly advised as opposed to noncontrast low-dose CT providing anatomic
data only [1, 34]. The sensitivity of PET-CT is impaired after chemotherapy [1, 35].
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In the early studies, liver US was considered effective in the follow-up after surgical treatment
of colorectal cancer metastases as it disclosed all the resectable cancer metastases as it disclosed
all the resectable with thoracic X-ray [36]. However, more recent data evidence that transab‐
dominal US has limited sensitivity in the diagnostics of CRC liver metastases: 50–75% [17].
Despite the serious shortcoming, US still can be used for screening purposes by experienced
specialist who is aware of these limitations and will combine US by more sensitive methods
of radiologic diagnostics. Intravenous contrast-enhanced US imaging using microbubbles to
contrast blood increases the sensitivity of US by 20% [17, 19] and exceeds the sensitivity of CT,
especially for small lesions [17]. Contrast-enhanced US affords diagnostic benefit in 13.7%
patients with liver mass lesions [19]. The increased sensitivity of contrast-enhanced US in
detection of tumours is explained by the vascularisation pattern and the phagocytosis of
contrasting microbubbles by Kupffer cells that are present in liver parenchyma but absent in
liver tumours. Thus, CRC metastases would be an adequate object for contrast US. The tumours
are hypoechoic. The sensitivity and specificity of US and contrast-enhanced US in diagnosing
malignant liver tumours is around 58.8% and 50.7% for US versus 68.7–90% and 67–88% for
the contrast-enhanced modality. Deep lesions, small metastases and liver steatosis are known
limiting factors. Colorectal cancer metastases may occasionally be hyperechogenic and lack
hypoechoic structure on contrast-enhanced US embarrassing differential diagnosis with
benign lesions, e.g., haemangioma [19].
Hepatic lesions can be missed even by combined radiologic investigation, including US, CT
and MRI. The proportion of such lesions can be as high as 30% [19]. Intraoperatively, US can
be applied. The sensitivity of intraoperative imaging is again enhanced by contrast US [37].
4. Preoperative radiologic evaluation: the target parameters
To plan the surgical treatment, the number, the size and the location of metastases must be
detected [1]. The number of affected segments, the relations between metastases and arteries,
veins and bile ducts as well as the size of remnant liver must be ascertained as well [18]. The
anatomical variations of bile ducts as well as arterial and portal blood vessels must be
established. CT or MRI can be used for these purposes. Although similar efficacy of both
methods has been shown regarding vascular anatomic evaluation, CT can yield better contrast
[1].
Diagnostic problems can be associated with identification of small lesions, imaging of meta‐
stases on the background of liver fibrosis, steatosis or sinusoidal congestion due to preceding
chemotherapy (or other reasons) and detailed characteristics of deep metastasis that necessi‐
tates careful planning of surgical approach and exact data on the involvement of anatomical
structures. Occasionally, differential diagnosis with benign lesions can be complicated. The
presence and extent of extrahepatic disease must be estimated [18].
Software-based three-dimensional CT volumetrics is used to calculate the volume of the
remnant and total liver volumes excluding nonfunctional spaces as tumours, cysts and ablation
cavities. The remnant liver volume is expressed as a proportion of the preoperative total liver
volume. The minimal volume of remnant liver has not been established by exact experimental
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studies therefore the described desirable values differ slightly. The remnant liver volume after
the operation is expected to be 25–30% in young patients with normal liver parenchyma and
40% in cirrhotic patients [4, 18]. In a consensus statement, remnant liver volume is recom‐
mended to be at least 20% for patients with normal extratumoural liver tissue, 30% for patients
having chemotherapy-induced liver injury and 40% in cirrhotic patients [17, 38–40]. As
metastatic tumour is spreading systemically and recurs in most patients, higher preserved
proportion of liver parenchyma provides more options for repeated future surgery if neces‐
sary. The risk factors for postoperative liver dysfunction due to insufficient remnant include
older age, liver fibrosis, cirrhosis and preoperative chemotherapy. Except liver cirrhosis, these
factors are frequent as many patients with CRC liver metastasis are elderly and have received
chemotherapy [4]. To estimate the compromised liver function more exactly, functional tests
are helpful. The liver function is reflected by albumin level, hemostasis, bilirubin level,
lidocaine conversion test or clearance of indocyanine green [18].
5. Traditional and novel tumour markers in the diagnostics of colorectal
cancer
The patients with metastatic colorectal cancer nowadays survive longer, thus they need
prolonged follow-up. CT is a sensitive method but some authors have expressed fears that the
patient is subjected to radiation exposure [41]. MRI benefits from high sensitivity and lack of
ionising radiation, but it is expensive. Blood test for surveillance thus seems to be an attractive,
patient-friendly and radiation-free option. Although the follow-up of colorectal cancer patients
after resection of the primary tumour is controversial, increased blood level of the carcinoem‐
bryonic antigen (CEA) can disclose cancer recurrence and is used traditionally. In a recent
study, 25% increase of CEA level in comparison with the previous value detected 23% of
recurrences while 46% of recurrences were evident both by radiology and CEA and 31%—only
by radiology data. The radiologic imaging in this study comprised US after surgical treatment
and CT after thermal ablation as well as in difficult cases. The resectability of the recurrent
cancer did not differ in patients who were identified through CEA or by imaging [41]. Thus,
CEA alone is not sensitive enough to identify the recurrence but can be helpful in complex
diagnostic protocol. In contrast, CEA alone did not identify any additional case of curable
recurrence after liver resection for metastatic colorectal cancer in comparison with CT [42].
CEA has several benefits, including cheapness and availability. In addition, prognostic
information can be obtained. High perioperative CEA levels indicate worse survival after liver
resection for CRC metastases [43].
CEA has been explored in association with other biological markers both for comparison and
in order to create wider diagnostic protocol. Regarding circulating tumour cells, the findings
along with CEA level added prognostic information in patients with metastatic colorectal
cancer undergoing chemotherapy. In a multivariate analysis, circulating tumour cells but not
CEA at the baseline predicted the survival, but both parameters predicted survival at 6–12
weeks after the initiation of treatment. There was no correlation between CEA and circulating
tumour cells [10]. The levels of circulating tumour cells in colorectal cancer are reported to be
lower than in other cancers due to homing within the liver [44]. The complex mechanism of
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metastasis involving epithelial–mesenchymal and mesenchymal–epithelial transformation as
well as blood clearing in the liver and secondary spread from liver metastasis to systemic
circulation hypothetically can influence the results and interpretation of circulating tumour
cell tests.
Plasma levels of the tissue inhibitor of matrix metalloproteinase 1 (TIMP-1) have also been
explored in parallel with CEA in patients undergoing chemotherapy for metastatic colorectal
cancer. High plasma TIMP-1 and CEA levels both before and during treatment were related
to poor response. Worse survival was predicted by high TIMP-1 level before or during
chemotherapy, and by high CEA values before treatment [45]. However, chemotherapy and
radiation treatment itself influenced serum levels of these markers, decreasing CEA and
increasing TIMP-1 [46]. The treatment-induced switches in the biomarker levels would limit
their application in the surveillance.
MicroRNAs (miRNAs) are small noncoding RNAs that post-transcriptionally modulate the
expression of the target genes [47, 48]. These endogenous molecules are evolutionarily highly
conserved, suggesting an important functional role in cell biology [48]. MiRNAs are located
either between protein-coding genes, or in the introns of protein-coding genes. Transcription
of miRNAs results in primary miRNAs that undergo processing within the nucleus. The
processing yields miRNA precursors that are transported to the cytoplasm and transformed
into mature miRNAs. These molecules perform their regulatory function by complementary
binding to mRNA [11]. miRNAs regulate such crucial steps in cancer development (Table 3)
as cell proliferation, invasion, angiogenesis, epithelial-mesenchymal transformation and the
reverse process [47]. The value of miRNAs is the ability to function as large genomic switches.
Target process Result MicroRNAs
Angiogenesis Activation miR-194; miR-17-92; miR-126; miR-210; miR-424
Suppression miR-221; miR-222; miR-497
Invasion Activation miR-31; miR-122; miR-200; miR-145; miR-103; miR-107;
miR-29a; miR-21; miR-17; miR-19a
Suppression miR-122; miR-328; miR-143
Metastasis Vascular invasion miR-21
Loss of cell adhesion miR-126
Immune regulation miR-155; miR-17-92
Colonisation miR-328; miR-103; miR-107
Apoptosis Induction miR-26b
Table 3. MiRNAs involved in different steps of carcinogenesis
From the practical standpoint, miRNAs at present are explored as diagnostic markers and
therapeutic targets [11]. In contrast to mRNA, miRNAs are stable in formalin-fixed, paraplast
embedded tissues [48–50]. In the blood and plasma, MiRNA also circulate in persistent form,
suitable for testing [51, 52]. The stability might be ensured by development of extracellular
microvesicles [52]. The specificity and sensitivity issues still must be finalised, but promising
Recent Advances in Liver Diseases and Surgery176
results have already been reported. Thus, 6 serum miRNA-based biomarker signature,
including miR-21, let-7g, miR-31, miR-92a, miR-181b and miR-203, had high sensitivity (93%)
and specificity (91%) in the diagnosis of colorectal cancer. The sensitivity of such traditional
serum markers as CEA and CA19-9 was significantly lower: 23% and 35%, respectively. The
tested panel could discriminate stage I and II colorectal cancer from healthy controls [12], thus
showing appropriate sensitivity for low tumour burden. Moreover, miR-92a, miR-21 and
miR-29a serum levels could discriminate healthy controls from patients affected by colorectal
cancer or advanced adenomas, the well-established precursor lesion of colorectal cancer [53,
54]. The levels of miR-17-3p, miR-92 and miR-221 also differed in plasma of colorectal cancer
patients and healthy controls [55, 56].
Early relapse of colorectal cancer is associated with increased plasma levels of miR-29c [48,
57]. More intense surveillance or postoperative treatment could be offered to these patients.
Patients with liver metastasis exhibit significantly higher miR-21 level in colorectal cancer
tissues. MiR-29a serum level is increased in colorectal cancer patients affected by liver
metastasis and is considered a promising novel marker for early detection of liver metastasis
[58]. In more recent studies, increased serum levels of miR-141 and miR-21 as well as down-
regulation of miR-126 were advised for early diagnosis of liver metastasis of colorectal cancer
while let7a up-regulation was associated with extrahepatic metastases [59]. The applicability
of this or similar biomarker signature for metastatic cancer remains to be subjected to deeper
analysis as at least few controversies can be expected. It has been shown in gastric and
hepatocellular carcinoma that serum and tissue levels of miRNAs can change in opposite
directions [60–62], possibly because cancer cells can selectively retain certain miRNAs [63]. In
colorectal cancer, liver metastasis exhibits higher levels of miR-29c, although miR-29c is
significantly down-regulated in primary colorectal cancers giving rise to distant metastasis.
The seeming controversy can be explained by epithelial–mesenchymal and mesenchymal–
epithelial transition [64]. In addition, surgical treatment can influence the miRNA level; thus,
in hepatocellular carcinoma, miR-92a levels are high in tumour tissue, low in plasma before
the treatment and high in plasma after the operation [61]. In colorectal cancer with liver
metastases, tissue levels of 28 miRNAs were different (Table 4) from nonmetastatic cancers
[65]. The tissue miRNA profile hypothetically could also discriminate between colorectal
cancer metastases in liver and lymph nodes [66].
MicroRNA Change in the target tissue
compared to the control
Target tissue or body liquid Control tissues or body
liquid
miR-21; let-7g Increase Plasma of cancer patients Plasma of healthy controls
miR-31; miR-181b; miR-92a;
miR-203
Decrease Plasma of cancer patients Plasma of healthy controls
miR-21 Increase Colorectal cancer Normal colonic tissue
miR-143 Decrease Colorectal cancer Normal colonic tissue
miR-21; miR-224; miR-96;
miR-31; miR-155
Increase Colorectal cancer Normal colonic tissue
miR-21 Increase Liver metastasis of colorectal
cancer
Normal colonic tissue
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MicroRNA Change in the target tissue
compared to the control
Target tissue or body liquid Control tissues or body
liquid
miR-143 Decrease Liver metastasis of colorectal
cancer
Normal colonic tissue
miR-21 No difference Liver metastasis of colorectal
cancer
Colorectal cancer
miR-143 Decrease Liver metastasis of colorectal
cancer
Colorectal cancer
miR-150; miR-125b-2;
miR-1179; miR139-3p
Increase Colorectal cancer with liver
metastasis
Colorectal cancer without
distant metastasis
miR-93; miR-548e; miR-19b;
miR-96; miR-548c-5p;
miR-140-5p; miR-19a;
miR-17-5p:9.1; miR-101;
miR-579; miR-18b; miR-18a;
miR-455-5p; miR-549;
miR-219-5p; miR-33b;
miR-330-5p; miR-301a
Decrease Colorectal cancer with liver
metastasis
Colorectal cancer without
distant metastasis
miR-196a-5p; miR-200b-3p;
miR-223-3p
Decrease Colorectal cancer with liver
metastasis
Colorectal cancer without
distant metastasis
miR-UL70-3p; miR-154-5p;
miR-221-3p; miR-301b;
miR-320b; miR-371a-5p;
miR-486-5p; miR-572;
miR-654-3p; miR-923
Increase Colorectal cancer with liver
metastasis
Colorectal cancer without
distant metastasis
miR-29c Decrease Colorectal cancer with liver
metastasis
Colorectal cancer without
distant metastasis
miR-29c Increase Liver metastasis of colorectal
cancer
Colorectal cancer
miR-21; miR-31; miR-93;
miR-103
Increase Colorectal cancer Normal tissues
miR-566 Decrease Colorectal cancer Normal tissues
miR-21; miR-31; miR-93 Increase Liver metastasis of colorectal
cancer
Normal tissues
miR-21 Increase Lymph node metastasis Normal tissues
miR-181a Increase Colorectal cancer with liver
metastasis
Colorectal cancer without
liver metastasis
1References: [12, 64–69].
Table 4. MiRNAs in colorectal cancer1
Prognostic value has been reported regarding has been reported. In colorectal cancer, shorter
disease-free interval was found in patients who exhibited higher miR-21 and higher miR-143
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levels in tumour tissues. Notably, in this study, higher miR-21 and lower miR-143 was found
in cancer and liver metastases in comparison to normal colonic and liver tissues [67]. The
seeming logic discrepancy between the prognostic levels and the differences in normal and
neoplastic tissues suggests multiple mechanisms of a single miRNA. These findings are
warning about high complexity in the elaboration of diagnostic tests. MiRNAs have also been
explored to predict the response to treatment. Thus, increased plasma concentrations of
miR-106a, miR-484 and miR-130 are associated with lack of response to oxaliplatin-based
treatment [48, 70]. Similar markers would be valuable to identify patients that would benefit
from preoperative tumour burden reduction by chemotherapy. The predicted nonresponders
could be treated by ablation techniques. As miRNAs function as large genomic switches, they
are also attractive potential targets of therapy [11].
6. Biopsy in the differential diagnostics of liver lesions
Biopsy evaluation can yield reliable diagnosis of colorectal cancer. The tubular and cribrous
glandular architecture in combination with high cylindrical neoplastic cells frequently is
straightforward (Figure 1). Upon necessity, immunohistochemical evaluation can be applied
as colorectal cancer is characterised by specific markers. Thus, the cytoplasmic expression of
cytokeratin 20 (Figure 2) and nuclear presence of CDX2 protein (Figure 3) is virtually diagnostic
of colorectal cancer.
Figure 1. Metastasis of colorectal cancer in liver tissue. Haematoxylin–eosin, original magnification 50×.
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Figure 2. Intense cytoplasmic expression of cytokeratin 20 in colorectal cancer. Note the heterogeneity. Immunoperoxi‐
dase, anti-cytokeratin 20, original magnification 50×.
Figure 3. Diffuse intense nuclear expression of CDX2 in colorectal cancer. Immunoperoxidase, anti-CDX2, original
magnification 100×.
In contrast to many other metastatic carcinomas, colorectal cancer lacks cytokeratin 7. Meta‐
static neuroendocrine tumours (Figures 4 and 5) can be excluded by the absence of chromog‐
ranin A, synaptophysin and CD56. The combination of several neuroendocrine markers is
advisable, especially in a patient with clinically and/or endoscopically identified colorectal
tumour, due to differential expression of these markers by gut origin (foregut versus midgut
versus hindgut). The clinical relevance of correct differential diagnosis between metastatic
colorectal adenocarcinoma and neuroendocrine tumours is high.
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Figure 4. Metastasis of neuroendocrine carcinoma in the liver tissue. Haematoxylin–eosin, original magnification 50×.
Figure 5. Metastasis of neuroendocrine carcinoma in the liver tissue. Immunoperoxidase, anti-chromogranin A, origi‐
nal magnification 50×.
In contrast to hepatocellular carcinoma, colorectal cancer lacks hepatocyte antigen, glypican
and cytoplasmic TTF-1 expression. Alpha-fetoprotein is absent from colorectal cancer tissues,
although the differential diagnostic value is lower because of relatively infrequent expression
in hepatocellular carcinoma. CD10 can be misleading in the differential diagnosis of hepato‐
cellular and metastatic colorectal cancer. Hepatocellular cancer mostly develops in the
background of liver cirrhosis while metastases are rare in cirrhotic liver. However, hepatocel‐
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lular carcinoma, and especially fibrolamellar variant, can arise in the absence of cirrhosis. In
contrast, colorectal cancer metastasis can be surrounded by liver tissue that is damaged by
peritumoural or treatment-related cell damage, fibrosis and inflammation [71].
The tissue analysis of cardinal tumour features and cancer microenvironment, production of
cytokinesand growth factors in the metastasis, evaluation of circulating neoplastic cells,
analysis of tumour hypoxia and angiogenesis atprotein, gene and miRNA levels can also bring
prognostic and predictive information [72–77]. Besides the tumour characteristics, hepatic
lymphatic anatomy and its involvement by tumour can be evaluated to predict the recurrence
[15].
7. Surgical treatment of the liver metastasis of colorectal cancer
The prognosis of metastatic colorectal cancer is serious. The 5-year survival of patients
receiving chemotherapy is low. In contrast, hepatic metastasectomy is an accepted procedure
with low perioperative mortality (2.3–2.8%) ensuring 5-year survival 28–58% and 10-year
survival 22-36% [15, 18, 78, 79]. The median survival of surgically treated patients is 42.5
months [4].
The CRC metastases can be treated surgically if all metastases can be completely resected, at
least 2 adjacent liver segments can be spared and sufficient liver function is expected [1].
The liver is composed of segments defined by vascular branching. As described by the
International Hepato-Pancreato-Biliary Association, the liver segments are unified in four
sections: left lateral and medial, right lateral and medial. Thus, segmentectomy, singular
sectionectomy, hemihepatectomy involving two sections and trisectionectomy can be per‐
formed [4]. Nonanatomic liver resection shows no differences from anatomic resection
regarding morbidity, mortality, recurrence rate or survival. In addition, it has the benefit of
parenchymal sparing providing more opportunities for repeated resections that are usually
limited by insufficient remnant liver. Nonanatomic resections can be carried out during shorter
operation time and are associated with less blood loss [80].
Extrahepatic vascular anatomy must be carefully considered before the operation as only 55%
of persons have typical arterial anatomy. Aberrant right hepatic arteries can arise from superior
mesenteric artery and from left gastric artery. The trifurcation of portal vein can be observed.
Computed tomography is the method of choice for vascular imaging [4].
Liver resection necessitates parenchymal dissection and haemostasis. The liver parenchyma
can be divided by finger-fracture or crush-clamp technique, by scissors using scratch or sharp
dissection technique, or by ultrasound or radiofrequency knives. Small vessels must be
occluded by bipolar coagulation, titan clipping or ligation. Bipolar or ultrasound coagulation
devices can be used for dissection and closure of small vessels. Larger vessels must be ligated.
Liver resection with staplers involves tissue dissection and automatic vessel clamping [4].
To limit the bleeding, total inflow occlusion can be used but can result in ischemia/reperfusion
injury if prolonged. Intermittent occlusion (15 min, alternating with 5 min of perfusion) better
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preserves liver function. Bleeding from hepatic veins can be decreased by low central venous
pressure (less than 4 mm Hg) or total vascular occlusion of the liver with or without in-situ
cooling of the liver [4].
Laparoscopic approach sincreasinglyapplied for liver resections, including even hemihepatec‐
tomy [4, 81]. The best indications for laparoscopic resection are single metastases, not exceed‐
ing 5 cm in diameter, in readily accessible segments 2–6. In contrast, segments 1, 7 and 8 are
considered difficult to access except for skilled professionals. Single incision laparoscopic
surgery has been used for liver resection but faces technical difficulties in spatial manoeuvres
with the instruments. As human ergonomics is limited, robotic surgery has been developed and
applied for liver resections facilitating the manipulations with the instruments and improv‐
ing the overview of operating field at the expense of remote contact with tissues and patient.
The lack of tactile feedback compromises the estimation of interaction strength and pressure
applied on the tissues. The conversion to open operation necessitates reorganisation of the
operation team [82]. Despite these shortcomings, in a recent review, robotic liver resection was
found to be a safe procedure [83]. Robotic malfunction is rare (2.4–4.5%). Major hepatecto‐
mies have been performed by robotic surgery [82]. However, the greatest advance of robotic
surgery can be the possibility to remove small, but hardly accessible lesions by small sectoral,
segmental or subsegmental resections instead of extensive routine liver resection [82, 84].
The surgical treatment can be precluded by involvement of portal vein, hepatic artery or
common bile duct. The goal of surgery is to resect all malignant tissue. If this would lead to
insufficient remnant liver, as in case of multiple bilobar metastases or deep metastases close
to hilum or major vessels, the surgery also is contraindicated [18]. To increase the size of liver
remnant, two-stage hepatectomy [85] or portal vein embolisation or ligation can be applied.
Both procedures take advantage of the regenerative capacity of the liver [4]. Portal vein
embolisation increases the resectability rate [86]. The portal vein occlusion can be performed
as intraoperative ligation of portal vein branches, transileocolic embolisation or percutaneous
transhepatic ipsilateral or contralateral embolisation. The spectrum of applied embolisation
materials includes polyvinyl alcohol particles, coils, gelatine sponge, fibrin glue, lipoiodol or
butyl cyanoacrylate. In a recent review, authors showed that preoperative portal vein embo‐
lisation has a high technical and clinical success rate. Liver cirrhosis impaired the regeneration.
However, cirrhosis is rarely encountered in association with metastatic cancers. Cholestasis
and preceding chemotherapy had no negative impact [87]. The resectability can also be
improved by chemotherapy-induced downstaging [86, 88, 89]. By chemotherapy, resectability
can be achieved in up to 40% of patients [90]. If the downstaging is successful and followed
by the resection, the 5-year survival reaches 33% that is comparable with the results in patients
with initially resectable metastases [86]. Preoperative chemotherapy is not indicated for
resectable lesions [89] and should not be excessively extended (9 cycles or more) to avoid
marked hepatotoxicity without improving the pathologic response [91]. Among the chemo‐
therapy-related liver damage, steatosis can be induced by 5-fluorouracil, nonalcoholic
steatohepatitis by irinotecan and sinusoidal obstruction syndrome by oxaliplatin [92]. For
successful downstaging, the type of chemotherapy is more important than the number of
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cycles. Thus, the inclusion of bevacizumab in the chemotherapy schedule in addition to
FOLFOX improves the outcome in terms of achieving resectability [91].
The planning of liver surgery can be challenging in patients presenting with colorectal cancer
and synchronous liver metastases. Simultaneous resection of primary tumours and liver
metastases can be performed in selected patients. Liver resection can safely be performed as
the first operation followed by the large bowel operation [93]. The safety of liver-first approach
has been confirmed in a recent review [94].
The risk factors of cancer recurrence include the presence of lymph node or extrahepatic
metastases, high CEA (above 200 ng/mL), multiple and large (above 5 cm) metastases, short
disease-free survival [18], high tumour grade and positive resection lines [4]. Regarding the
resection line, the minimal requirements are under discussion regarding R0 resection with
distance between tumour and resection line less than 1 cm. In the recent literature, lack of 1
cm margin is not considered a contraindication for liver resection [80], and generally the
requirement for tumour-free tissue border has decreased from 10 to 2 mm or even 0 mm [95–
98]. The presence of hilar lymph node metastases is an adverse prognostic factor in comparison
to metastases affecting only liver but can be less hazardous in prognostic terms than metastases
in lymph nodes adjacent to truncus coeliacus or aorta [4].
After resection, MRI or CT should be used for surveillance. The examinations must be repeated
every 3–6 months for 2 years after resection and every 6 months for 3–5 years after the surgery
[1]. Perioperative chemotherapy, including adjuvant treatment, increases recurrence-free
survival [99].
8. Liver transplantation for colorectal cancer metastases
Liver transplantation is indicated for end-stage chronic liver disease and acute liver failure. In
addition, transplantation has certain indications regarding malignant tumours. The classic
indications include hepatocellular carcinoma on the background of liver cirrhosis if the patient
corresponds to the Milan criteria; fibrolamellar hepatocellular carcinoma, hepatoblastoma and
epithelioid haemangioendothelioma. Transplantation is researched in patients having
hepatocellular carcinoma with tumour burden exceeding the Milan criteria, hepatocellular
carcinoma in noncirrhotic liver, cholangiocellular cancer and liver metastases from neuroen‐
docrine tumours. Hepatocellular carcinoma with extrahepatic spread or portal vein invasion,
hepatoblastoma with uncontrolled extrahepatic spread and other malignancies are regarded
as contraindications for liver transplantation. Thus, until recently, colorectal cancer metastases
to the liver also were considered a contraindication for liver transplantation [100] due to
allocation justice in the background of organ shortage and due to the risk of tumour recurrence
on the background of immunosuppression.
A revolutionary approach has been undertaken in Norway by Hagness et al. offering liver
transplantation  to  patients  with  unresectable  liver  metastases  of  colorectal  cancer.  The
resulting life  quality  was good.  The 5-year  survival  was  60%,  that  exceeds the  survival
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obtained by chemotherapy and is comparable to the survival after liver resection in suitable
cases [9].
Interestingly, the recurrence patterns after liver transplantation differ from those after liver
resection. The most frequent event is single-site recurrence in the lungs, followed by recurrence
in multiple sites. In the present group of patients, no single-site recurrences in liver were
observed, although the liver was involved by tumour metastases in patients having recurrence
in multiple sites. Regarding the outcome, the pulmonary metastases followed indolent course,
but metastases to the transplanted liver were prognostically adverse. The immunosuppressive
treatment did not enhance the growth of those pulmonary metastases that were present at the
time of transplantation [9]. The m-TOR inhibitors used for immunosuppression can have
beneficial influence as they block angiogenesis and proliferation [9, 100].
9. Nonsurgical treatment of liver metastases of colorectal cancer
Although surgical treatment ensures the best 5-year survival, only 15–25% of liver metastases
are amenable to resection [98]. If surgical treatment is not possible, radiofrequency ablation,
cryotherapy, microwave ablation, stereotactic body radiotherapy, radioembolisation or
percutaneous alcohol injection canbe used to decrease the tumour burden [101, 102]. Generally,
ablation therapies are not recommended for resectable lesions [103].
The liver metastases can be targeted by radiofrequency ablation although the benefits of it are
controversial. Positive estimates have been published [104, 105]. However, later data showed
that radiofrequency ablation alone or in combination with surgery resulted in inferior survival
in comparison with liver resection. The outcome of radiofrequency ablation was only slightly
better than the results of chemotherapy [39]. The resulting 5-year survival was around 24%
[106–110]. Still later, 5-year survival of 43% has been reported [98]. After the procedure, either
local recurrence or new liver metastases can develop. The risk of local recurrence is higher if
the lesion is larger than 3 cm: 21.7% vs. 1.6–3.8% [111–113]. The development of new metastases
predominates over local recurrence and can be promoted by liver regeneration and production
of cytokines [98, 113]. To avoid complications, proximity to bile ducts but not vessels is of
utmost importance as the blood vessels are moderately sensitive to heat and can be protected
by vascular clamping and Pringle manoeuvre involving alternation of clamping and perfusion.
In contrast, bile ducts are very sensitive to heat-induced damage [113].
Radiofrequency ablation belongs to the group of thermal ablation procedures comprising
also laser-induced interstitial thermotherapy. In this method, laser light is directly transmit‐
ted to the neoplastic tissue through flexible optic fibres, and the absorption of laser photon
energy causes local rise of temperature inducing coagulation necrosis. The results are highly
dependent on the completeness of tumour destruction. The 5-year survival after thermal
ablation is 44% if the ablation is complete and 20% if it is partial. The frequency of partial
ablation  ranges  from  38%  to  52%  [114–116].  The  size  of  neoplastic  mass  is  the  main
predictive  factor  for  the  completeness  of  the  ablation,  with  better  results  achieved  in
metastases smaller than 3 cm [116, 117].
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Cryoablation involves tissue destruction by low temperature, i.e., intended freezing of the
target in order to induce local necrosis. Although percutaneous, laparoscopic or open surgical
approach generally is possible, cryotreatment of liver tumours is mostly performed via open
surgical access. Occasionally, laparoscopic approach is used [118]. The temperature is de‐
creased by liquid nitrogen or argon gas that is delivered to the target by special probe under
US guidance. The freezing is rapid, so the formed ice crystals destroy the cells, including
tumour cells. Ice crystals also propagate in the microvessels. The procedure includes alternat‐
ing cycles of freezing and thawing. Multiple masses are treated consecutively rather than
simultaneously. Necrosis develops within the next 2 days and is well-demarcated in the third
to fourth day after the procedure. Large masses (>5 cm) are not amenable to complete treat‐
ment. Another limitation includes tumours close to large blood vessels [119]. Cryoablation
ensures 5-year survival in 17% of patients [109, 120–122].
In microwave ablation, tissue destruction is induced by microwaves. The electrode is inserted
in the tumour mass under US or CT guidance using percutaneous, laparoscopic or open
surgical access. An alternating high-frequency (900–2450 Hz) electromagnetic field induces
vibration of water molecules representing dipoles. The energy created by the induced
movement of water molecules is released as heat that results in coagulative necrosis [3]. The
method can ensure wider and quicker tissue destruction than radiofrequency ablation. It is
not limited by the temperature 100°C, does not rely on the conduction of electricity and is less
limited by impedance of the destroyed tissues or scars [123]. The 5-year survival after micro‐
wave ablation was 16% in the older reports [109, 124, 125]. Recently, intraoperative microwave
ablation ensured 4-year survival of 35.2% [123] and 3-year survival of 36% [126].
External  beam  radiation  treatment  for  liver  metastases  has  limited  effect  due  to  high
sensitivity  of  hepatocytes  towards  ionising  radiation.  Thus,  therapeutic  radiation  doses
would induce serious liver damage but small  doses lack efficacy.  The treatment of liver
metastases by external beam radiation is associated with high rate of local recurrence and
side effects, both contributing to low survival. Three-dimensional conformal radiotherapy
is more targeted. In stereotactic body radiation treatment, a robotic arm is used to target
the lesion in synchronisation with the respiratory movements. This allows delivering higher
radiation dose to the lesion while retaining appropriate safety profile with only tolerable
complications. After stereotactic body radiation treatment, the 1-year survival of complex,
pretreated patients with the frequent presence of extrahepatic metastases was 45.5% [110].
The 2-year survival is reported to be 45% [127].
Hepatic arterial infusion can be applied due to the fact that metastases larger than 3 mm receive
95% of blood supply from the hepatic artery. This technique yields higher concentration (up
to 16 times higher) of the medication within the metastasis in association with lower systemic
toxicity due to concentrated supply and first-pass effect with maximum absorption in the liver.
Skilled team and qualitative radiologic imaging are the prerequisites [102]. There are several
technically related approaches that also involve direct supply of the therapeutic agent to the
target via hepatic artery, such as placement of hepatic arterial infusion pumps, selective
internal radiation therapy, drug-eluting bead embolisation and irinotecan-containing drug-
eluting particles [128].
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Although successful  surgery can yield long term survival,  recurrence develops either in
liver  or  in  other  distant  sites  in  60–70%  of  patients  [15].  Therefore,  adjuvant  systemic
chemotherapy,  hepatic  arterial  infusion  chemotherapy  and  molecular  targeted  therapy
represent  important  adjuncts  to  surgical  treatment.  Systemic  chemotherapy  results  in
significantly better survival [129,  130] but can cause systemic adverse effects along with
vascular liver damage and steatosis [131]. Hepatic arterial infusion of specific chemothera‐
peutic  agents  has  the  benefits  of  directly  targeting the  metastasis  within  liver  and thus
causing  less  systemic  toxicity.  However,  biliary  tract  damage  can  follow  [132,  133].
Monoclonal antibodies against VEGF and EGFR are attractive by the targeted mechanism
[101,  134].  However,  bevacizumab,  cetuximab  and  panitumumab  have  also  caused
controversies regarding liver metastases of colorectal cancer [13].
10. Radiologic evaluation before nonsurgical treatment
In general, the metastatic process must be characterised similarly as before the operation. If
ablation is planned, the relation between the metastasis and the intrahepatic bile ducts and
vessels must be carefully established to avoid heat-induced damage [1]. If the medical centre
has the necessary skills to provide hepatic artery infusion with chemotherapeutic agents for
neoadjuvant therapy to decrease lesion size and allow resection, for adjuvant for treatment
after resection or treatment of unresectable liver disease, hepatic artery must be visualised by
CT angiography [18].
11. Radiologic assessment of the treatment outcome
Classically, the tumour response to treatment is measured by decrease of the tumour mass
diameter as defined by the Response Evaluation Criteria in Solid Tumours (RECIST). The
RECIST criteria, described in 2000 and refined in 2009 [1, 135, 136], necessitate one-dimensional
measurements to detect the sum of maximal diameter of five lesions. The relative difference
of this parameter before and after treatment is interpreted as follows: progressive disease,
increase of at least 20% and at least 5 mm in the sum, or appearance of a new lesion; stable
disease, lack of dynamics or changes within the borders between progressive disease and
partial response; partial response, decrease for at least 30%; and complete radiologic response,
disappearance of all lesions. It must be emphasised that radiologic complete response is not
always equivalent to pathologic complete response; therefore, all the responded lesions still
must be removed surgically [17]. Several controversies exist regarding RECIST criteria. First,
it is suggested that early response for 10% correlates with the outcome better than the border
of 30% [17, 137]. Further, not only size but also the composition of the mass lesion matters as
it can include not only viable tumour but also necrosis, fibrosis, granulations or haemorrhage.
By ablation techniques, the surrounding liver tissue is intentionally damaged and fuses
together with the metastatic mass. After intra-arterial treatment by chemotherapy, drug-
eluting beads, irinotecan drug-eluting beads or radio embolisation, the response evaluation is
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confounded by haemorrhage, necrosis resulting in size enlargement, peripheral thin rim of
granulation tissue mimicking metastasis, fibrosis, peritumoural ischemia or hepatitis [1].
Therefore, the evaluation of treatment response includes not only the changes in the lesionsize,
but also its morphology and functional status [17].
Morphologic radiologic features, including changes in tumour heterogeneity and internal
structure, enhancement and margins, can indicate favourable tumour response to treatment
[138]. On CT, CRC metastases in the liver have heterogeneous structure and ill-defined
margins. Responding lesions obtain homogeneous structure and outlined margins [17]. The
morphologic response on CT correlates with pathologic response and with the survival [138].
PET-CT characterises the metabolic activity in the lesions [1], suggesting pathogenetically
substantiated accurate estimate of tumour response. However, the sensitivity of PET decreases
after chemotherapy [17]. Clinically importantly, PET can identify lack of chemotherapy
efficacy just after 1 cycle [139].
Preceding treatment can induce not only tumour shrinkage but also liver parenchymal
damage. By CT, steatosis that affects more than 30% of parenchyma can be diagnosed by the
liver attenuation index characterising the difference in the attenuation between liver and
spleen. By MRI, the analysis of water and fat proton signals is possible, leading to more accurate
estimates of steatosis than by CT and US [1, 140]. Sinusoid obstructive syndrome can be caused
by oxaliplatin-based chemotherapy. It is characterised by sinusoidal injury that may lead to
fibrosis or veno-occlusive disease. The radiologic findings are nonspecific [1].
12. Complete radiologic response
Complete radiologic response can be obtained in 5–38% of patients. The frequency of complete
radiologic response depends on the efficacy of preoperative treatment and on the quality and
completeness of radiologic investigation. Metastasis can become difficult to observe on CT if
the size decreases and/or the surrounding liver tissue develops steatosis. MRI can be used to
identify the residual lesions. The MRI-documented disappearance of the metastasis is sugges‐
tive of true complete histologic response.
The correlation between radiologic and pathologic complete response ranges 20–100% in
different studies. Thus, at present, all sites of disease should be resected surgically. A fraction
of lesions (up to 24% of patients with complete response on CT) can be grossly identified during
the operation. Full mobilisation of liver and palpation, followed by intraoperative conven‐
tional and contrast-enhanced US, are the subsequent options rising the yield to 45% of patients.
Contrast-enhanced US identifies additional 10–15% of nodules, compared with palpation and
conventional ultrasonography technique. The intraoperative yield is lower in patients who
have had preoperative MRI, suggesting that MRI is the method of choice to identify true small
residual metastases that are missed by less sensitive CT [17].
If the radiologically regressed metastases are not resected, they tend to recur. The frequency
of durable clinical response, usually defined as disease-free period for 1 year, correlates with
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the frequency of complete pathologic response. The recurrence mostly develops in 10–20
months. The median time to recurrence is 11 months. The recurrence occurs more frequently
in patients who have unresected radiologically disappeared metastases in comparison to those
who underwent the surgery, although a more effective adjuvant treatment can diminish these
differences. Hepatic arterial infusion treatment lowers the incidence of intrahepatic recurrence
and increases the frequency of durable response similarly as increasing the rate of complete
pathologic response [17].
13. Survival
The median survival of patients affected by metastatic colorectal cancer has increased signif‐
icantly, e.g., from 27.3 months in 1994 to 39.4 months in 2007 [13]. Analogous increase in the
survival is reported also by other authors [14]. The 5-year and 10-year survival can reach even
58% and 36%, correspondingly [15]. Lower 5-year survival after surgical treatment has been
reported earlier, e.g., 25–40% [78, 110, 141–144], contrasting with the 5-year survival of 15% in
patients with unresectable metastases [33, 145, 146]. The 10-year survival of 25–26% has been
described [123, 147, 148]. Better survival is observed in case of delayed metastases [14].
14. Conclusions
1. In conclusion, liver metastases of colorectal cancer must be treated surgically whenever
possible as surgery ensures the best survival.
2. Contraindications for surgery include wide tumour spread within the liver or to extrahe‐
patic organs, expected insufficient liver remnant and poor general status. Neoadjuvant
treatment should be attempted to downstage the tumour.
3. If the metastatic lesions are not amenable to surgery,ablation or radiation modalities can
be applied in association with chemotherapy.
4. High-quality radiologic investigation is necessary to reveal the metastases of colorectal
cancer. Magnetic resonance imaging is considered the most sensitive technique that has
remarkable advantages revealing subcentimeter metastases and lesions within steatotic
liver. Computed tomography benefits from high discrimination and can be used to replace
magnetic resonance.
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